Ology Bioservices Wins Three Department of Defense Awards Totaling More Than $16 Million
The company will manufacture a conjugated vaccine candidate being developed to prevent the disease melloidosis.
Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced in a July 7, 2020 press release that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.
In the first program, valued at $8.5 million, the company will manufacture a conjugated vaccine candidate being developed to prevent the disease melloidosis. The candidate, developed at the University of Nevada, Reno, will be tested in a Phase 1 clinical trial. It is made up of the conserved protein from the bacterium Burkholderia pseudomallei and the adjuvant CPS-CRM-197.
In the second program, valued at $4.6 million, the company will manufacture outer membrane vesicles from Burkholderia mallei as a potential vaccine against the bacterial disease glanders. The vaccine candidate was developed at Tulane University, and the material will support a Phase 1 clinical trial.
In the third program, valued at $3.2 million, the company will manufacture a DNA vaccine against Venezuelan equine encephalitis to support a Phase 1 clinical trial. The vaccine was developed at the United States Army Medical Research Institute of Infectious Diseases.
Source: Ology Bioservices
